Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
Datian Chen,1 Kaikai Gu,2 Huiyu Wang3 1Department of Oncology, Haimen People’s Hospital, Haimen, People’s Republic of China; 2Haimen Hospital of Traditional Chinese Medicine, Haimen, People’s Republic of China; 3Wuxi People’s Hospital Affiliated to Nanjing Med...
Main Authors: | Chen DT, Gu KK, Wang HY |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-02-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/optimizing-sequential-treatment-with-anti-egfr-and-vegf-mab-in-metasta-peer-reviewed-article-CMAR |
Similar Items
-
Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis
by: Datian Chen, et al.
Published: (2018-10-01) -
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
by: Hiromichi Nakajima, et al.
Published: (2021-06-01) -
Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis
by: Lola-Jade Palmieri, et al.
Published: (2022-03-01) -
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
by: Ilaria Marrocco, et al.
Published: (2021-04-01) -
CLINICAL EXPERIENCE OF COMBINED AVASTIN THERAPY IN METASTATIC COLORECTAL CANCER
by: V. A. Ekimov
Published: (2015-02-01)